Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEM-PD Trial
NCT05635409Phase 1Active, not recruiting
- Sponsor
- Region Skåne
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label trial of stem cell-derived dopamine neurons in Parkinson's disease (PD) (2 arms), sponsored by Region Skåne. Primary endpoints: Adverse Events and Serious Adverse Events at 12 months and Absence of space occupying masses on cranial MRI at 12 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
stem cell-derived dopamine neurons
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05635409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635409.